Cardiol Therapeutics Inc Class A (CRDL.TO) is seeing a positive shift in the market, with shares up by 1.63% in the last trading session.
In a typically volatile market, Cardiol Therapeutics has secured a gain of 1.63% today, closing at CA$1.55. This increase shows investor confidence in the company’s ongoing developments and strategic initiatives.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol Therapeutics as it continues to make progress in the biotech sector, especially with its promising cardiac therapies and recent financial moves.
1.63% Increase in Stock Price
Cardiol Therapeutics' stock rose to CA$1.55, reflecting positive market sentiment amid ongoing developments in their clinical programs.
Bull case
The recent rise in Cardiol's stock price likely comes from solid operational updates and successful financing rounds that have strengthened its cash position. This financial boost allows the company to further develop its innovative therapies.
Bear case
Even with today’s gain, investors should stay cautious. The biotech sector carries risks, including regulatory challenges and the possibility of clinical trial failures that could affect future stock performance.
Recent Developments
Cardiol Therapeutics has been actively advancing its clinical programs, including the Phase III MAVERIC trial and the CRD-38 program. Recent financial maneuvers, such as a successful bought deal financing, have improved its balance sheet, enabling the company to pursue its innovative therapies more aggressively.
Market Sentiment
The positive movement in Cardiol's stock can be linked to investor optimism surrounding its operational updates and the potential impact of its therapies on cardiac health. With a market cap of about CA$176 million, investors are closely monitoring the company’s growth trajectory.
Looking Ahead
As Cardiol Therapeutics continues its research and development efforts, investors should watch for updates on clinical trial results and regulatory approvals that could significantly influence stock performance in the coming months. For more detailed insights, check out our analysis on CRDL.TO.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
